GLP1R and Parkinson disease: EcN‐GLP‐1 could persistently produce and deliver active GLP‐1 drug molecule that can cross the BBB and bind to its receptors localized in neurons throughout the brain, which would activate the pathway of GLP‐1/GLP‐1R to exert the therapeutic effects on PD (Figure 7).